Related Experiment Video
Updated: Feb 16, 2026

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
Published on: May 10, 2022
FOXO3 induces ubiquitylation of AKT through MUL1 regulation
Sun-Yong Kim1, Hyo Jeong Kim1,2, Hyung Kwon Byeon3,4
1Department of Otolaryngology, Ajou University School of Medicine, Suwon, Republic of Korea.
Abstract:
AKT (also known as protein kinase B, PKB) plays an important role in cell survival or tumor progression. For these reasons, AKT is an emerging target for cancer therapeutics. Previously our studies showed that mitochondrial E3 ubiquitin protein ligase 1 (MUL1, also known as MULAN/GIDE/MAPL) is suppressed in head and neck cancer (HNC) and acts as negative regulator against AKT. However, the MUL1 regulatory mechanisms remain largely unknown. Here we report that cisplatin (CDDP) induces thyroid cancer cell death through MUL1-AKT axis. Specifically, CDDP-induced MUL1 leads to ubiquitylation of active form of AKT. We also observed that the role of forkhead box O3 (FOXO3) is pivotal in CDDP-induced MUL1 regulation. FOXO3 knock-downed cells show resistance against CDDP-mediated MUL1-AKT axis. CDDP-mediated intracellular ROS increment plays an important role in FOXO3-MUL1-AKT signal pathway. The data provide compelling evidence to support the idea that the regulation of FOXO3-MUL1-AKT axis can be a novel strategy for the treatment of HNC with CDDP.
Insights
Cisplatin triggers thyroid cancer cell death by activating the mitochondrial E3 ubiquitin ligase 1 (MUL1) and inhibiting AKT. This pathway, involving FOXO3 and reactive oxygen species (ROS), offers a new strategy for head and neck cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- AKT (protein kinase B) is crucial for cell survival and tumor progression, making it a key target in cancer therapy.
- Mitochondrial E3 ubiquitin protein ligase 1 (MUL1) is downregulated in head and neck cancer (HNC) and negatively regulates AKT.
- Mechanisms controlling MUL1 function are not fully understood.
Purpose of the Study:
- To investigate the role of the MUL1-AKT axis in cisplatin-induced thyroid cancer cell death.
- To elucidate the regulatory mechanisms of MUL1, particularly the involvement of FOXO3 and reactive oxygen species (ROS).
- To explore the potential of targeting the FOXO3-MUL1-AKT pathway for HNC treatment.
Main Methods:
- Investigated cisplatin (CDDP) effects on thyroid cancer cells.
- Analyzed the ubiquitylation of active AKT mediated by MUL1.
- Examined the role of forkhead box O3 (FOXO3) and intracellular ROS in the CDDP-induced pathway.
Main Results:
- CDDP treatment increases MUL1 expression, leading to ubiquitylation and inactivation of active AKT.
- FOXO3 is essential for CDDP-induced MUL1 regulation; FOXO3 knockdown confers resistance to CDDP.
- CDDP-induced intracellular ROS increment is a critical component of the FOXO3-MUL1-AKT signaling pathway.
Conclusions:
- CDDP induces thyroid cancer cell death via the FOXO3-MUL1-AKT axis.
- FOXO3 acts as a key regulator in this pathway, mediating MUL1's tumor-suppressive function.
- Targeting the FOXO3-MUL1-AKT pathway presents a potential novel therapeutic strategy for HNC treatment with CDDP.
More Related Videos
Related Concept Videos
GTPases and their Regulation
Large G-proteins,...
PI3K/mTOR/AKT Signaling Pathway
Master Transcription Regulators
Epigenetic Regulation
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Hormonal Regulation

